Several Indian companies, including Larsen & Toubro, Godrej Consumer Products, and Dr Reddy’s Laboratories, are expected to record double-digit growth in their topline and bottomline figures for the March quarter due to healthy execution and strong order books. L&T’s core engineering business is expected to drive the topline with a healthy opening order book. Meanwhile, Revlimid, the cancer drug, is expected to have contributed significantly to growth in Dr Reddy’s US sales.
Sustained deal momentum, discretionary pick up hint at a better FY26 for Infosys
Infosys reported better-than-expected revenue and net profit growth for Q4 2024, increased its FY25 revenue guidance, and plans to hire more freshers. The steady recovery
January 16, 2025